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Global proteomic analysis of
prenylated proteins in Plasmodium
falciparum using an alkynemodified isoprenoid analogue
Kiall F. Suazo1, Chad Schaber2, Charuta C. Palsuledesai1, Audrey R. Odom John2 &
Mark D. Distefano1
Severe malaria due to Plasmodium falciparum infection remains a serious threat to health worldwide
and new therapeutic targets are highly desirable. Small molecule inhibitors of prenyl transferases,
enzymes that catalyze the post-translational isoprenyl modifications of proteins, exhibit potent
antimalarial activity. The antimalarial actions of prenyltransferase inhibitors indicate that protein
prenylation is required for malaria parasite development. In this study, we used a chemical biology
strategy to experimentally characterize the entire complement of prenylated proteins in the human
malaria parasite. In contrast to the expansive mammalian and fungal prenylomes, we find that
P. falciparum possesses a restricted set of prenylated proteins. The prenylome of P. falciparum is
dominated by Rab GTPases, in addition to a small number of prenylated proteins that also appear to
function primarily in membrane trafficking. Overall, we found robust experimental evidence for a total
of only thirteen prenylated proteins in P. falciparum, with suggestive evidence for an additional two
probable prenyltransferase substrates. Our work contributes to an increasingly complete picture of
essential, post-translational hydrophobic modifications in blood-stage P. falciparum.
Over the past 15 years, improved efforts at controlling malaria, caused by infection with the protozoan parasite
Plasmodium falciparum, have significantly decreased the overall number of cases and childhood deaths attributable to severe malaria1. However, there remain over 200 million infections and over half a million deaths due
to malaria each year2. Access to highly effective antimalarial therapies remains a cornerstone of malaria control efforts. Unfortunately, widespread resistance to former first-line agents, such as chloroquine, and emerging
resistance to newer treatments, such as the artemisinin-combination therapies, endangers control of malaria
worldwide3,4.
Target-based antimalarial drug development depends on identification of essential biological processes in
P. falciparum that are amenable to small molecule inhibition. Development of therapeutics for the developing
world is hampered by a relative lack of commercial pharmaceutical interest. Therefore, one strategy has been to
identify potential antimalarial target proteins whose human homologs have themselves been explored as pharmaceutical targets. These kinds of repurposing approaches thus harness the power of previous large-scale small
molecule screening and development pipelines, in hopes of reducing the effort and expense of developing novel
antiparasitics for resource-limited settings.
Protein prenyltransferases have emerged as one such “piggybacking” target for antimalarial drug development5,6. Protein prenylation is the C-terminal modification of cellular proteins with either a farnesyl (15-carbon)
or geranylgeranyl (20-carbon) isoprenyl group. Prenyl modification of proteins is catalyzed by several classes
of cellular prenyltransferase enzymes, including farnesyl transferase (FT) and geranylgeranyltransferase type I
and type II (GGT-1 and GGT-2)7,8. Prenylation is typically required for the membrane association and therefore
the cellular activity of prenyltransferase substrates. For example, farnesylation of the small G-protein oncogene,
K-Ras, is required for the transformation of many human cancers, including lung and colon cancer9. For this
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reason, protein farnesyltransferase inhibitors have been extensively explored by the pharmaceutical industry as
potential human chemotherapeutics10,11. Like most eukaryotic organisms, P. falciparum malaria parasites also
possess protein prenyltransferase activity and have been found to incorporate both farnesyl and geranylgeranyl
modifications into protein substrates12,13. Chemical inhibition of isoprenoid precursor biosynthesis in malaria
parasites blocks protein prenylation and is lethal to cultured P. falciparum, suggesting that production of isoprenyl
substrates for protein prenylation is an essential function of isoprenoid biosynthesis in the parasite14. In addition,
inhibition of parasite prenyltransferase activity halts parasite replication15–18, providing compelling evidence that
protein prenylation is indispensable for malaria parasite growth.
Since protein prenyltransferase activity is required by P. falciparum, identification of prenyltransferase substrates will likely reveal additional antimalarial targets. Bioinformatic approaches have been previously used to
predict a limited number of potential prenylated proteins in the malaria genome19. However, since Plasmodium
spp. are evolutionarily divergent from organisms used to generate these models, and few prenylated proteins have
been experimentally confirmed in malaria parasites, it is not clear how well bioinformatics algorithms perform in
predicting prenyltransferase substrates for Plasmodium spp. In this work, we use a chemical labeling approach to
metabolically tag, potentially, the full complement of prenylated proteins in asexual P. falciparum parasites. Our
approach was to metabolically incorporate an alkyne-modified isoprenoid analogue into the pool of prenyltransferase protein substrates. This additional alkyne functional group permits selective binding of prenylated proteins
to streptavidin beads, via click chemistry with biotin-azide. The resulting prenylated proteins were identified by
subsequent tryptic digestion and LC-MS analysis, coupled with bioinformatics analysis.

Results

An alkyne-functionalized isoprenoid analogue is metabolically incorporated into malaria parasites.

To identify the prenylated proteins in P. falciparum using an alkyne-containing isoprenoid analogue, we first
tested for metabolic incorporation of the compound C15AlkOPP (Fig. 1A), which was previously employed to
identify prenylated proteins in mammalian cells20,21. This probe structurally resembles the native isoprenoid substrates farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) used for prenylation of proteins,
and is a substrate for both mammalian FT and GGT-122. Red blood cells infected with P. falciparum were exposed
to the probe in the presence or absence of fosmidomycin (FSM), an established inhibitor of isoprenoid biosynthesis in P. falciparum23,24, followed by release of the intact parasites via mild detergent treatment. The free parasites
were then lysed and the resulting lysates subjected to copper-catalyzed click reaction with TAMRA-N3, which
generates a stable cycloaddition product between the alkyne-tagged prenylated proteins and TAMRA-N3 to allow
visualization of labeled proteins (Fig. 1B). The samples were then fractionated via SDS-PAGE and subjected to
in-gel fluorescence imaging (Fig. 1C, top panel).
Fluorescent protein bands were observed at approximately 25 and 50 kDa in samples obtained from parasites
treated with C15AlkOPP (lane 3); a number of weaker bands, including species near 37 and 150 kDa, were also
observed. A substantial enhancement of labeling ensued upon co-administration of FSM (lane 4), suggesting that
depletion of the endogenous FPP pool results in increased incorporation of the analogue; similar results with
C15AlkOPP have been observed in mammalian cells treated with lovastatin20. Replacing the probe with FPP
showed only limited labeling in these regions (lane 2), indicating that the alkyne analogue is a viable tool to tag
cellular prenylated proteins.
It should be noted that P. falciparum parasites develop within human erythrocytes. Although human prenyltransferases have not been identified in the mature erythrocyte proteome25, we evaluated for the possibility that
human erythrocyte proteins could incorporate C15AlkOPP probe in the absence of parasite infection. Human
red blood cells were thus also treated with C15AlkOPP and FSM, and did not demonstrate significant labeling
(lane 1). The band observed above 25 kDa is almost certainly an artifact due to a highly abundant protein band
in this region as shown in the Coomassie stained gel (Fig. 1C, bottom panel); given its size, that protein may
represent a hemoglobin dimer26. Overall, these results indicate that the C15AlkOPP probe successfully labels
prenylated proteins in the malaria parasite with minimal interference from human proteins.

The C15AlkOPP probe is elongated by P. falciparum FPPS/GGPPS.

As noted above, C15AlkOPP is
a substrate for the mammalian FT and GGT-1 enzymes. Previously reported metabolic labeling data suggests that
C15AlkOPP can also be used to label substrates of GGT-2. However, those results do not preclude elongation of
C15AlkOPP to C20AlkOPP prior to prenyltransferase-catalyzed incorporation. Hence, we next sought to investigate whether C15AlkOPP can be elongated to C20AlkOPP in malaria parasites. Unlike other organisms that
express a series of prenyl synthases, P. falciparum produces a single multi-functional enzyme (PfFPPS/GGPPS,
hereafter PfFPPS) that is responsible for synthesis of geranyl pyrophosphate, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate27,28. To evaluate whether the parasite enzyme may utilize the C15AlkOPP probe as a
substrate, we assayed purified recombinant PfFPPS protein. As expected, PfFPPS uses IPP to elongate its natural
substrate, FPP, thus generating GGPP. Similarly, we found that PfFPPS also effectively uses C15AlkOPP as a
substrate (Fig. 2). Thus, while it is not clear whether the elongated analogue is a substrate for the malarial GGTs,
the production of that species maximizes the likelihood that our single probe strategy using C15AlkOPP will
function to tag both farnesylated and geranylgeranylated proteins in the parasite.

Bioinformatic analysis of the P. falciparum proteome affords a list of putative prenylated proteins.

To date, only a limited number of proteins with canonical C-terminal prenylation motifs have been demonstrated to be bona fide substrates in P. falciparum14,29–31. Prior to proteomic analysis, we performed a bioinformatic investigation to create a list of all possible prenyltransferase substrates present in the P. falciparum
proteome. FASTA sequences of proteins from the Plasmodium falciparum genome reference isolate 3D7 proteome
(UniProt ID UP000001450) with possible C-terminal –CaaX, –CXC, and –CC prenylation motifs were analyzed
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Figure 1. The C15AlkOPP probe allows tagging of prenylated proteins for in-gel fluorescence labeling
and pulldown for proteomic analysis. (A) Structures of native isoprenoid substrates of prenylation, farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), and the probe analog C15AlkOPP.
(B) Scheme for metabolic labeling using the C15AlkOPP probe followed by selective labeling or enrichment
using click chemistry. In-gel fluorescence and proteomic analysis of prenylated proteins were facilitated
through click reactions with fluorescent reporter TAMRA-N3 and affinity handle biotin-N3, respectively.
(C) Labeling of prenylated proteins visualized through in-gel fluorescence (top panel) in P. falciparum lysates.
Lane 1: C15AlkOPP + FSM in red blood cells; lane 2: FPP + FSM in Pf; lane 3: C15AlkOPP in Pf; lane 4:
C15AlkOPP + FSM in Pf. Total protein loading by Coomassie blue stain is shown in purple (bottom panel).

Figure 2. P. falciparum farnesyl pyrophosphate synthase (PfFPPS) accepts C15AlkOPP as a substrate.
Specific activity (mean ±  S.E.M.) of PfFPPS, measured using an absorbance-based phosphate release assay. Left
to right, enzyme activity in the presence of FPP and IPP, C15AlkOPP probe and IPP, or C15AlkOPP alone. No
activity was seen in absence of PfFPPS (data not shown). Three replicates were performed for each condition.
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Accession No.

Name

C-term

Mol. wt. (kDa)

Q8I346

SNARE protein (putative)

KKQCCSIM

23

Q8I583

Ulp1 protease (putative)

ISQGCLVF

123

Q8IKN0

Uncharacterized protein

QRRMCNIM

38

Q8IEC5

Uncharacterized protein

KKKKCTIM

95

PrePS
FT***
GGT-1***
FT*
GGT-1*
FT*
GGT-1**
FT***
GGT-1***

Q8IL88

Hsp40 subfamily A (putative)

GRVACAQQ

48

C0H5D3

SNARE protein (putative)

NNQCCSLY

26

FT**
FT*

Q8IE80

Uncharacterized protein

NIAACKQC

34

FT*

Q8IEK2

Uncharacterized protein

NRLKCNIM

73

GGT-1**

Table 1. Candidate prenyl transferase substrates from the P. falciparum 3D7 proteome, which contain
canonical CaaX motifs and were identified by PrePS. PrePS was used to predict the likelihood of prenylation of
the proteins identified: *low, **intermediate, ***high. Underlined residues indicate putative sites for prenylation.

Accession No.

Name

C-term

Mol. wt. (kDa)

Basic residue at
−1 to −5

Hydrophobic
residue at +2

Aromatic
residue at +2
+

Q8IIN1

Protein tyrosine phosphatase

NCLRKCHFM

25

+

+

Q8ILH7

Uncharacterized protein

KKRNKCNFM

51

+

+

+

Q8I3K7

Membrane skeletal protein IMC1-related

QRNLYCSYA

34

+

+

+

Q8I0W8

Deoxyribodipyrimidine photolyase

KREKKCVAS

129

+

+

−

O77306

Ser/Thr protein kinase

NKKNSCAYT

157

+

+

−

Q9NLB7

Uncharacterized protein

NYNFLCLYI

10

−

+

+

O77380

CPSF

DLENMCSFL

339

−

+

+

Table 2. Candidate prenyl transferase substrates from the P. falciparum 3D7 proteome, which were not
identified by PrePS but possess additional, promising CaaX features. Underlined residues indicate putative
sites for prenylation.
using Prenylation Prediction Suite (PrePS)32. Out of 90 protein sequences with Cys at the 4th position from the
C-terminus (–CaaX), a total of 8 proteins were predicted to be prenylated (Table 1). This group contains 5 proteins whose molecular masses are close to 25, 37, 50, and 150 kDa, similar to what we observed experimentally
via in-gel fluorescence labeling (Fig. 1C). Furthermore, five of these proteins contain basic residues upstream
of the putatively prenylated Cys, a typical pattern observed for most prenylated proteins. In addition to these
predicted proteins, we examined those that were not recognized by PrePS but met additional criteria for prenylation: basic residues upstream of Cys at the −1 to −5 positions and a hydrophobic or aromatic residue at the +2
position. Seven proteins that satisfy these additional parameters were thus identified from the proteome database
(Table 2). A previous study reported 8 proteins that satisfied these criteria based on the P. falciparum genome,
which included a DEAD/DEAH box Helicase and Methionyl-tRNA formyltransferase (along with six of the seven
predicted in our analysis)30. However, neither of these two proteins contains a C-terminal CaaX sequence in the
reference Plasmodium falciparum isolate 3D7 proteome database (although one of them does in another database,
see Figure S1). Interestingly, the remaining protein listed in Table 2 (but not identified in the aforementioned
genomic analysis), PRL protein tyrosine phosphatase, does appear to be a real prenylated protein. Recent computational docking studies33 suggested that it is a substrate and this has been confirmed through additional in vitro
assays30.
Proteins with C-terminal –CXC and –CC motifs were also extracted from the proteome and analyzed in
PrePS. As expected, Rab proteins were predicted to be substrates of geranylgeranyl transferase type II (GGT-2)
with high degrees of probability (Table 3). The molecular weights of these small GTPases are consistent with the
bands observed near 25 kDa via in-gel fluorescence labeling (Fig. 1C). No proteins other than those belonging
to the Rab family were identified as potential substrates, suggesting that there are no known proteins with these
–CXC and –CC sequences that have the specific neighboring residues upstream of Cys necessary to render them
substrates for GGT-2. In aggregate, our bioinformatic analysis using PrePS suggests that the P. falciparum proteome contains 8 –CaaX, 3 –CXC, and 7 –CC proteins (18 total) that may be prenyltransferase substrates.

Proteomic analysis of the prenylated proteins in P. falciparum.

After validating the use of
C15AlkOPP as a prenylation probe in P. falciparum, we next sought to determine the molecular identity of
prenylated proteins in the parasite. To reduce cellular production of FPP, which would compete with probe
incorporation, cultured asexual P. falciparum were treated with sub-lethal (50% of the half-maximal inhibitory concentration) concentrations FSM. Fosmidomycin-treated parasites were grown in the presence of either
C15AlkOPP probe or FPP as a negative control. Following labeling, parasites were freed from host erythrocytes,
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Accession No.

Name

C-term

Mol. wt. (kDa)

PrePS

Q8IL79

Copper transporter putative

ADPACCGC

27

No

Q8IM51

Secreted ookinete adhesive protein

ECSCSCSC

23

No

Q8IHR8

Rab6

NMLSKCLC

24

GGT-2**

Q7K6B0

Rab18

ESRSNCAC

23

GGT-2***

Q8I3W9

Rab1a

SPQSFCSC

24

GGT-2***

-CXC

-CC
Q8IHW0

Myosin heavy chain subunit, putative

ELNMFKCC

208

No

C6KST4

Uncharacterized protein

IKKKKMRCC

33

No

Q8II49

Conserved Plasmodium protein

TKKFFPCC

30

No

Q8IHW1

Conserved Plasmodium protein

KTKKCYCC

19

No

Q8IAL1

Uncharacterized protein

GKRFLGCC

9

No

Q7K6A8

Rab1b

KDTKKKCC

23

GGT-2***

O96193

Rab5a

TLSKKGCC

27

GGT-2***

Q8I274

Rab5c

EETKKKCC

24

GGT-2***

Q76NM4

Rab11a

TKKKNKCC

25

GGT-2***

Rab2

SRSGFSCC

24

GGT-2***

Q8I5A9
C0H516

Rab7

KMYKSRCC

24

GGT-2***

C0H5G2

Rab11b

NMNKVKCC

24

GGT-2**

Table 3. Candidate prenyl transferase substrates from the P. falciparum 3D7 proteome, which possess –
CXC and –CC C-terminal motifs for possible geranylgeranylation. PrePS was used to predict the likelihood
of prenylation of the proteins identified: *low, **intermediate, ***high. Underlined residues indicate putative
sites for prenylation.

and parasite protein lysates were subjected to click reaction with biotin-N3; the affinity handle conferred by biotin
permits the selective enrichment and isolation of labeled prenylated proteins upon pull-down through the strong
biotin-avidin interaction (Fig. 1B). Proteins were washed under stringent conditions (1% SDS and 8 M urea) followed by on-bead trypsin digestion. Equal amounts of peptides from C15AlkOPP- and FPP-treated samples, were
pre-fractionated and analyzed by nano-flow liquid chromatography and tandem mass spectrometry (MS/MS),
followed by database searching against Plasmodium falciparum (UniProt ID UP000001450) and Homo sapiens
proteomes (UniProt ID UP000005640). After data processing, 445 proteins were identified at 99.0% minimum
probability with at least 2 identified peptides from 9073 spectra, and 98.0% minimum peptide confidence within
a 1% false discovery rate, for both C15AlkOPP- and FPP-treated samples.
Our labeling strategy was designed to enrich for prenyltransferase substrates labeled with C15AlkOPP and/
or C20AlkOPP using a biotin pull-down approach. Proteomic studies that use such enrichment methods are
sometimes complicated due to nonspecific adsorption of proteins onto the avidin-coated beads used in these
experiments. To address that issue, our approach employed a quantitative comparison based on spectral counting
between the samples treated with C15AlkOPP and those treated with FPP. We used the average total spectral
counts for each identified protein to calculate the enrichment of proteins (fold-change) across three replicates
of samples treated with C15AlkOPP probe versus FPP. The full list of spectral counts and identities are provided
(Supplemental Table S1). Proteins with potential prenylation motifs (–CaaX, –CC, –CXC on their C-terminus)
were extracted from that data and summarized in Table 4. A total of 15 prenylated proteins are listed, including 14 of the 18 predicted in our bioinformatics analysis. One additional protein (Q81LH7) bearing the –CaaX
sequence CNFM, which was not predicted by PrePS, was also identified. Conversely, four of the –CaaX sequences
predicted by PrePS were not observed (Q81583, Q81EC5, Q81E80 and Q81EK2 with –CaaX sequences CLVF,
CTIM, CKQC and CNIM, respectively). All Rab proteins predicted to be prenylated by PrepPS were identified.
The list of all proteins identified in our analysis (Supplemental Table S1) is ordered based on the fold change
between the C15AlkOPP- and FPP-treated samples. The top 12 proteins in that list correspond to the first 12
entries in Table 4 (9 to 33-fold change). For each of these top 12 hits, very few spectral counts were observed in the
absence of probe, giving high confidence that these represent bona fide prenylated proteins. In contrast, numerous proteins were found below the 6-fold threshold. In those cases, substantial spectral counts were observed in
the absence of probe; we attribute those proteins to nonspecific adsorption. However, the last 3 entries in Table 4,
while manifesting low levels of spectral counts in the C15AlkOPP-treated samples, gave no spectral counts in the
FPP-treated samples, suggesting that they may represent true, low abundance hits; one of those three, SNARE
Ykt6.1, has been confirmed as a prenyltransferase substrate31. It is worth noting that the aforementioned DEAD/
DEAH box Helicase and Methionyl-tRNA formyltransferase suggested by previous investigators as possible prenylated proteins based on bioinformatics analysis30 are not present in the list of proteins in Table S1. Finally, it
should be noted that human Rab homologs were also identified and grouped into clusters with the parent proteins
from P. falciparum (Supplementary Table S1 and Figure S2), since the data analysis was conducted using both the
H. sapiens and P. falciparum databases. However, for each identified Rab, the change in spectral counts in the presence of probe was always higher for the candidate malarial proteins than their human homologs. Additionally,
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Percent coverage
(%)

Spectral
Count
Protein
Name
Rab6
HSP40 sub
family A
Rab7
Rab1b
Rab1a
Rab2
Rab5c

Accession Noa./
Gene IDb
Q8IHR8
PF3D7_1144900
Q8IL88

Biological Processc

Cellular
Componentc

C15AlkOPP

FPP

Fold
Change

C15AlkOPP

FPP

C-term
sequencec

Confirmed
prenylation

PrePSd

vesicular transport
(putative)

trans Golgi,
cytosolic29

33,32,33

0,0,0

33

70,70,59

0,0,0

NMLSKCLC

Yes29

GGT-2**

protein folding43,
protein translo

cytosolic,
RBC

39,34,37

1,2,0

28

41,35,33

2,5,0

GRVACAQQ

No

FT**

cation (putative)54

membrane43

24

retrograde transport55

endosomes55

25,27,25

0,0,0

26

59,66,66

0,0,0

KMYKSRCC

No

GGT-2***

23

ER to Golgi transport
(putative)40

ER, Golgi
(putative)40

19,12,17

0,0,0

16

37,35,31

0,0,0

PDTKKKCC

No

GGT-2***

24

ER to Golgi
transport40

ER, Golgi40

11,10,12

0,0,0

11

17,21,22

0,0,0

SPQSFCSC

No

GGT-2***

24

ER to Golgi transport
(putative)40

ER, Golgi
(putative)40

25,21,28

2,0,0

18

58,56,57

11,0,0

SRSGFSCC

No

GGT-2***

24

retrograde transport14

endosomes14

18,15,14

0,0,0

16

43,35,33

0,0,0

EETKKKCC

Yes14

GGT-2***

Mol. wt.
(kDa)a
24
48

PF3D7_1437900
C0H516
PF3D7_0903200
Q7K6A8
PF3D7_0512600
Q8I3W9
PF3D7_0513800
Q8I5A9
PF3D7_1231100
Q8I274
PF3D7_0106800

formation of inner
membrane

Q76NM4
Rab11a

25

complex56, recycling
endosome transport
(putative)

vesicles56

12,17,12

0,0,0

14

41,42,41

0,0,0

TKKKNKCC

No

GGT-2***

27

retrograde transport14

endosomes14

9,9,11

0,0,0

9.7

25,29,29

0,0,0

TLSKKGCC

Yes14

GGT-2***

23

mobilization of lipid
droplets (putative)57

Parasitophorous vacuole
mem brane
(putative)57

9,7,11

1,1,1

9

28,24,28

6,6,6

ESRSNCAC

No

GGT-2***

24

transport (putative)

8,10,9

0,0,0

9

30,25,31

0,0,0

NMNKVKCC

No

GGT-2**
FT*

PF3D7_1320600
Rab5a

O96193
PF3D7_0211200
Q7K6B0

Rab18

Rab11b

PF3D7_0807300
C0H5G2

membrane
(puta

PF3D7_1340700
C0H5D3

SNARE
Ykt6.2

PF3D7_1324700

SNARE
Ykt6.1

PF3D7_0910600

Uncharacterized

PF3D7_1460100

Uncharacterized

PF3D7_1428700

Q8I346
Q8IKN0
Q8ILH7

tive)
26

vesicular fusion,
transport (putative)58

membrane
(putative)

5,6,7

0,0,0

6

14,18,24

0,0,0

KNNQCCSLY

No

23

vesicular fusion,
transport (putative)58

Golgi,
cytosolic,
vacuolar31

3,2,2

0,0,0

2.3

17,13,11

0,0,0

LKQCCSIM

Yes58

38

PI3P binding,
trafficking to the food
vacuole59

food vacuole
lumen59

0,2,1

0,0,0

1.3

0,8,5

0,0,0

QRRMCNIM

No

0,1,3

0,0,0

1.7

0,3,5

0,0,0

KRNKCNFM

No

51

FT***
GGT-1***
FT*
GGT-1**
—

Table 4. Prenylated proteins in Plasmodium falciparum, identified by C15AlkOPP labeling and proteomics,
with –CaaX, -CXC, and –CC prenylation motifs. For each protein, fold-change indicates the ratio of the
average total spectral counts obtained following C15AlkOPP- versus FPP-labeling, across three experimental
replicates. An imputation of 1 was employed to calculate fold changes. Spectral counts and percent coverage for
each replicate are shown. Two uncharacterized proteins (protein identifiers and associated data are italicized)
containing predicted prenylation motifs were identified with low spectral counts. Underlined residues indicate
putative sites for prenylation. aProtein accession numbers including theoretical molecular weights and bgene IDs
were obtained from UniProt and PlasmoDB, respectively. CUnless otherwise referenced from previous reports,
biological processes and cellular component of identified proteins were obtained from UniProt. dPrePS was used
to predict the likelihood of prenylation of the proteins identified: *low, **intermediate, ***high.

we found, in each case, that protein probabilities for parasite sequences were higher than those for the cognate
human orthologs. Together, these characteristics indicate that the Rab proteins identified upon metabolic labeling
of P. falciparum are indeed malarial in origin and that the human candidates are artifacts of sequence similarities.

Discussion

Due to the ongoing spread of drug resistance, there is a pressing need for new therapies to treat malaria. Evidence
strongly suggests that protein prenylation is required for asexual development of the P. falciparum malaria parasite; several distinct chemotypes of prenyltransferase inhibitors exhibit potent antimalarial activity15,16,18,34–36.
Given the essential nature of protein prenylation, it follows that the functions of prenyltransferase substrates
themselves are necessary for parasite replication. Thus, identification of prenylated proteins in P. falciparum may
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reveal new, essential, and highly valuable targets for antimalarial drug development. Such targeting could be
accomplished either indirectly by interfering with prenylation or directly via inhibition of their cognate functions.
Here we present the first experimentally determined catalog of prenylated proteins (the “prenylome”) of blood
stage P. falciparum. We have identified prenyltransferase substrates through the use of metabolic labeling with
a novel, alkyne-containing isoprenoid analogue. We find that the P. falciparum farnesyl pyrophosphate synthase
(FPPS) successfully elongates the probe (which is a derivative of FPP) to generate the cognate 20-carbon (GGPP
derivative) probe. Therefore, we believe our in vivo metabolic labeling approach has likely captured the full complement of both farnesylated and geranylgeranylated proteins in P. falciparum, with the exception of prenylated
proteins with very low levels of expression during blood-stage development that may not react in our derivatization strategy.
Eukaryotic systems possess three different protein prenyltransferases: farnesyltransferase (FT) and geranylgeranyltransferase type I (GGT-1) commonly recognize the same motif (the CaaX box) that includes the cysteine
of their substrates they modify, and are thus referred to as CaaX prenyltransferases, whereas geranylgeranyltransferase type II (GGT-2, also called Rab geranylgeranyltransferase) recognizes an alternative motif37. Active
prenyltransferases consist of two polypeptide subunits, α and β; FT and GGT-1 typically share an α subunit.
As has previously been suggested19, we find that experimentally confirmed prenyltransferase substrates of
P. falciparum parasites possess canonical motifs that indicate the presence of both CaaX prenyltransferases and
Rab geranylgeranyltransferases. P. falciparum lysate has previously been shown to possess both FT and GGT-1
activity12. The current annotation of the P. falciparum genome indicates a full complement of genes encoding
the candidate prenyltransferases, as follows: PfFT [PF3D7_1242600 (αsubunit) and PF3D7_1147500 (β subunit)], PfGGT-1 [PF3D7_1242600 (αsubunit; shared with PfFT) and PF3D7_0602500 (βsubunit)], and PfGGT-2
[PF3D7_1442500 (αsubunit) and PF3D7_1214300 (β subunit)].
Our work experimentally confirms that protein prenylation in P. falciparum reflects a more modest set of
prenylated proteins than is observed in fungi or higher eukaryotes, including humans. According to PRENbase
(http://mendel.imp.ac.at/PrePS/PRENbase/), a curated online database of protein prenylation across sequenced
genomes, prenylated proteins in the human genome are spread into 43 clusters of paralogous proteins38. Biological
functions of prenylated proteins are well conserved, even amongst unicellular eukaryotes, as 42 similarly defined
clusters are present across fungal genomes. In stark contrast, we find robust experimental evidence for a total
of only thirteen prenylated proteins in P. falciparum, with suggestive evidence for an additional two probable
prenyltransferase substrates. While a restricted prenylome has been suggested bioinformatically for malaria parasites, our study provides important evidence that there are not unrecognized, non-canonical motifs used by the
P. falciparum prenyltransferases.
During asexual replication, P. falciparum is an obligate parasite of human erythrocytes, and relies on
vesicle-mediated trafficking of erythrocyte cytoplasm and hemoglobin, as well as export of essential proteins for
remodeling of the erythrocyte membrane and cytoplasm. The importance of membrane trafficking to P. falciparum development is underscored by the restricted biological functions of the malaria prenylome. Interestingly,
we find that the majority of proteins in the P. falciparum prenylome belong to a single cluster of paralogous proteins, the Rab family of small GTPases, classic regulators of endomembrane trafficking. These proteins likely make
up the broad band at 25 kDa found in our in-gel fluorescence images upon C15OPP labeling (Fig. 1C), as well
as in studies using radiolabeling of parasites with [3H]-geranylgeranyl pyrophosphate39. Unsurprisingly, of the
eleven Rabs annotated in P. falciparum, we found all ten predicted to be geranylgeranylated by GGT-240.
In addition, three more prenyltransferase substrates in P. falciparum (two SNARE proteins and a phosphatidylinositol 3-phosphate binding protein) are also likely to function in membrane trafficking. Notably absent
from the P. falciparum prenylome are a number of GTPase superfamilies, including Ras and Rho, typical of other
unicellular eukaryotes and metazoans. This restricted use of protein prenylation for a single biological function
reflects the complement of small GTPases that has been suggested to have been present in the last common eukaryotic ancestor, prior to the dramatic expansions of paralogous GTPase gene families41,42. The limited collection of
GTPases and prenylated proteins that we find in P. falciparum is therefore not unique to this parasite, but is shared
with other Alveolates in this lineage, including several other important mammalian parasitic pathogens, such as
Cryptosporidium, Toxoplasma, and Eimeria.
We identify only four confirmed prenylated proteins in P. falciparum that possess a canonical CaaX motif,
which should serve for recognition and modification by either FT or GGT-1. Bioinformatic analyses are insufficient to indicate whether a given CaaX-containing protein is farnesylated or geranylgeranylated. However,
experimental evidence suggests that at least one of these proteins, PF14_0359, a Hsp40 analog, is specifically
farnesylated. In P. falciparum, metabolic labeling with [3H]-farnesyl pyrophosphate, but not [3H]-geranylgeranyl
pyrophosphate, identifies a dominant band at approximately 50 kDa39. As the remaining proteins in the malaria
prenylome are between 23–38 kDa, this finding most likely represents farnesyl modification of PfHsp40
(48 kDa)43.
P. falciparum expresses an expanded repertoire of molecular chaperones, comprising 2% of the overall
genome, and including 49 Hsp40 superfamily members in total44. However, while other eukaryotes typically
express up to five type I Hsp40s, PfHsp40 is the sole, cytosolic type I Hsp40 homolog in the malaria parasite.
In other organisms, farnesylation of orthologous type I Hsp40s has been well described, and is required for the
biological functions of these chaperones in mediating protein stability45,46. The cellular function of PfHsp40 in
P. falciparum has yet to be explored, although immunofluorescence microscopy indicates that this protein is
cytosolic43. However, data from proteomics and yeast two-hybrid studies indicate it may play a role in trafficking
to the RBC membrane47. The extent to which farnesylation plays a role in the localization or functions of PfHsp40
remains to be explored.
Our work contributes to an increasingly complete picture of post-translational hydrophobic modifications
in blood-stage P. falciparum. The identification of a limited set of CaaX proteins has important implications for
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understanding the evolution of this modification process, as well as the active work developing novel antimalarial
therapies targeted to isoprenoid synthesis and prenyltransferases.

Methods

P. falciparum tissue culture. All culturing was done with Plasmodium falciparum genome reference strain
3D7. 3D7 was obtained from the Malaria Research and Reference Reagent Resource Center (strain MRA-102,
contributed by D. J. Carucci, ATCC, Manassas, Virginia). Parasites were grown in RPMI-1640 media (SigmaAldrich, SKU R4130) supplemented with 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM
sodium pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 μg ml−1 gentamycin (Sigma-Aldrich) and 0.5%
Albumax (Life Technologies) with a 2% suspension of human erythrocytes under an atmosphere of 5% CO2,
5% O2, balance N2 and incubated at 37 °C, as previously described24,48. For in-gel fluorescence, 40 mL of culture
was used per replicate. Samples destined for mass spectroscopy analysis were derived from 200 mL of culture
per replicate. For all experiments, cultures were adjusted to 4% of red blood cells infected (4% parasitemia) at
experiment start. Cultures were treated with fosmidomycin (Life Technologies) to a final concentration of 600 nM
(approximately half IC50). Pyrophosphate probes or prenyl pyrophosphates (Echelon Biosciences) were added to
a final concentration of 10 μM. After compounds were added, cultures were mixed thoroughly and incubated for
24 hours.
After 24 hours, cultures were saponin lysed as previously described24, with modifications. In brief, cells were
pelleted and washed with PBS before being lysed with 1% saponin in PBS. Saponin lyses red blood cell (RBC)
membranes but not parasite cell membranes, thus freeing the parasites from the RBCs. The lysed mixture was
pelleted, and the loose RBC membrane layer and supernatant removed, leaving a parasite pellet. This pellet was
washed with PBS, centrifuged again, the supernatant removed, and stored at −80 °C.
RBC controls were performed with 5 mL per replicate of 2% hematocrit in supplemented RPMI media with
no parasites. RBCs were pelleted without saponin since internal RBC proteins are released with lysis. This volume
corresponds to the volume of saponin-freed parasites from 200 mL total culture at 4% parasitemia.
In-gel fluorescence labeling. RBC controls and saponin-lysed pellets of P. falciparum, treated with or without FSM and FPP or C15AlkOPP, were suspended in 300 μL lysis buffer (10 mM PO43−, 137 mM NaCl, 2.7 mM
KCl, 2.4 μM PMSF, benzonase nuclease, protease inhibitor cocktail and 1% SDS) and sonicated 6 to 8 times for
2 seconds in 10-second intervals. Click reactions were performed on 100 μg samples of protein lysate (1 μg/μL)
with 25 μM TAMRA-N3, 1 mM TCEP, 0.1 mM TBTA, and 1 mM CuSO4 at room temperature for one hour.
Proteins were precipitated using a ProteoExtract precipitation kit (Calbiochem) to remove excess click chemistry
reagents. Protein pellets were dissolved in 1X Laemlli loading buffer and heated at 95 °C for 5 minutes. Samples
were fractionated using 12% SDS PAGE gels and imaged via in-gel fluorescence using a BioRad FX Molecular
Imager with 542/568 nm excitation/emission wavelengths. Gels were stained with 1X Coomasie blue stain followed by destaining to visualize protein loading.
Cloning and expression of PfFPPS.

The gene PfFPPS (PF3D7_1128400) was PCR amplified from
P. falciparum 3D7 cDNA (primers PfFPPS Fwd 5′-CTCACCACCACCACCACCATGCUGAGAACGAGCAG
AATAACCAAGATTC-3′; PfFPPS Rev 5′- ATCCTATCTTACTCACTCAAGCGCCTGTAAACAAAATGTCC-3′)
and cloned into pBG1861 using ligation independent cloning as previously described49. The cloned PfFPPS
sequence was verified by Sanger sequencing. The primers used add coding for a six histidine tag at the N-terminus
of the gene to allow for nickel affinity purification.
Subsequently, pBG1861 was transformed into ArticExpress (DE3) RIL E. coli (Agilent Technologies). Cultures
were grown in LB media with 100 μg/mL ampicillin at 37 °C and 200 rpm until mid-log phase, at which point they
were cooled to 8 °C. Expression was induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 5 μM
geraniol and 5 μM farnesol overnight at 8 °C and 200 rpm. Following induction, cells were pelleted and then lysed
by sonication in a solution of 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MgCl2, 10% v/v glycerol, 20 mM imidazole, 1 mM dithiothreitol (DTT), 1 mg/mL lysozyme, 200 μM phenylmethylsulfonyl fluoride (PMSF) 0.3 U/mL
benzonase nuclease (Novagen), and EDTA-free protease inhibitor (Roche). 6-histidine tagged protein was purified from soluble lysate over Ni-NTA resin (Goldbio). The resin with bound protein was washed with 25 mM Tris
pH 7.5, 250 mM NaCl, 1 mM MgCl2, 10% v/v glycerol, 20 mM imidazole, 1 mM dithiothreitol (DTT). Bound protein was then eluted with 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MgCl2, 10% v/v glycerol, 300 mM imidazole,
1 mM dithiothreitol (DTT).
Next, the elutant was further purified over a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthcare)
using an AKTAExplorer 100 FPLC (GE Healthcare). The FPLC buffer was 250 mM NaCl, 25 mM Tris pH 7.5,
and 1 mM MgCl2, 10% glycerol v/v. Fractions enriched with PfFPPS, as seen by a strong band at ~44 kDa on a
Coomassie-stained SDS-PAGE gel, were pooled and concentrated by centrifugation using Amicon Ultra-15 centrifugal filter units (EMD Millipore). Concentrated protein was supplemented with 1 mM DTT, was flash-frozen
in liquid N2, and was then stored at −80 °C prior to use. Protein concentration was measured by a BCA protein
assay kit (Thermo Scientific).

Isoprenyl pyrophosphate synthase assay. Following purification, release of pyrophosphate during
GGPP/C20AlkOPP synthesis from FPP/C15AlkOPP by PfFPPS was monitored using the EnzChek phosphate
assay kit (Life Technologies), as previously described50. Reactions were performed in a 50 μL volume, with final
reagent concentrations as follows: 250 mM NaCl, 50 mM Tris pH 7.5, 1 mM MgCl2, 1 U/mL purine nucleoside
phosphorylase (PNP), 0.2 mM 2-Amino-6-mercapto-7-methylpurine riboside (MESG), 0.1 U/mL yeast inorganic pyrophosphatase (New England Biolabs), and 2 μM purified PfFPPS, and, where indicated, 100 μM IPP,
FPP (Echelon Biosciences) and/or C15AlkOPP. All reagents save PfFPPS were pre-warmed to 37 °C. Reactions
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were initiated by the addition of PfFPPS, after which absorbance at 360 nm was recorded over a 30 min period
with a BMG POLARStar plate reader preheated to 37 °C. Absorbance monitoring was performed in clear 96-well
flat-bottomed plates. Enzyme reactions were linear with respect to time and enzyme concentration. Absorbance
units were converted to μM phosphate using a phosphate standard curve.

Pull-down of labeled proteins.

Protein lysates (1.5 mg/mL) from parasites treated with FSM and FPP or
C15AlkOPP were subjected to click reactions with 100 μM biotin-N3, 50 mM TCEP, 10 mM TBTA, and 50 mM
CuSO4 for 90 minutes at room temperature. Excess reagents were removed by protein precipitation using 1 volume
of chloroform, 4 volumes of CH3OH, and 3 volumes of PBS. Proteins were precipitated in between two immiscible phases by centrifugation at 4,500 ×  g for 5 minutes. The aqueous layer was discarded and 4 volumes of CH3OH
was added, followed by centrifugation at 4,500 ×  g for 3 minutes to pellet the proteins. Proteins were dissolved in
1% SDS in PBS buffer (1.5 mg/mL) and incubated with 300 μL of NeutrAvidin agarose resin (Thermo Scientific)
for 90 minutes. Resin samples were washed to remove unbound proteins with 3-mL volumes of 3 × 1% SDS in
PBS, 1 ×  PBS, 3 × 8 M urea, and 3 × 50 mM NH4HCO3. Resin was suspended in 300 μL of 50 mM NH4HCO3 and
combined with 5 μg trypsin (sequencing grade, Promega Corp.) for overnight digestion at 37 °C. Supernatants
were collected by washing the resin with 200 μL × 4 of 50 mM NH4HCO3 and samples were lyophilized.

®

Proteomic analysis. Sample preparation for MS/MS analysis. Lyophilized peptides were dissolved in
200 mM NH4COO. Aliquots from resulting peptide solutions (20 μg) were obtained to prepare 0.25 μg/μL solutions. Each sample was loaded in SDB-XC extraction disk (3 M, USA) packed in stage tips conditioned with 80%
acetonitrile (ACN) and equilibrated with 200 mM NH4HCO2. Samples were washed with 200 mM NH4HCO2 and
eluted into three fractions using 40 μL of 6%, 11%, and 17% ACN in H2O. Each sample was dissolved in 100 μL of
5% ACN and 0.1% TFA in H2O and loaded onto packed extraction disks in stage tips that were conditioned (80%
ACN and 0.1% TFA in H2O) and equilibrated (5% ACN and 0.1% TFA in H2O). Peptides were eluted with 80%
ACN with 0.1% TFA in H2O, lyophilized, and dissolved in 0.1% formic acid.
LC-MS/MS analysis of tryptic digested peptides. LC-MS/MS analyses were carried out using an RSLCnano
System (Dionex, UK) and an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). Samples were
directly loaded and eluted at a flow rate of 300 nL/min onto a reverse-phase column (75 μm i.d., 450 mm) packed
with ProntoSIL C18AQ 3 μm media (Bischoff, Germany) that was prepared in-house. The peptides were eluted
with buffer A (0.1% formic acid in H2O) and buffer B (0.1% formic acid in CH3CN) in the following gradient
segments of buffer B: 17 mins, 0–2%; 60 mins, 2–25%; 2 mins, 25–44%; 2 mins, 44–76%; 3 mins, 76%; and 2 mins,
76–2%. The eluted peptides from the column were sprayed into a nanospray ion source on an Orbitrap Fusion
Tribrid mass spectrometer set to record single microscan FTMS scan events at a resolution of 30000 over the m/z
range 300–1500 Da in positive ion mode, with charge states of 2–7 included. The top 15 data-dependent CID MS/
MS were triggered from the FTMS scan and introduced into the Orbitrap- Fusion ion trap. The collision energy
was set to 35% and activation Q to 0.25 with the scan range and ion trap scan rate both set to normal. The automatic gain control (AGC) target values were set to optimal conditions using 500,000 for MS1 and 5,000 for MS251.
Dynamic exclusion was allowed once for a 90-second duration.
Proteomic data processing. The raw files were searched using Sequest embedded in Proteome Discoverer (version
1.4.0.288, Thermo Scientific) against the Plasmodium falciparum 3D7 isolate (ID UP000001450) appended with
Homo sapiens (ID UP000005640) from UnipProtKB/SwissProt52. The precursor mass tolerance was set to 10 ppm
and the fragment mass tolerance was set to 0.6 Da. A variable modification was set as oxidized methionine. The
enzyme was set to Trypsin (Full) and up to 4 missed cleavages were allowed. A decoy search was also performed.
The resulting msf files were processed in Scaffold (version 4.4.1, Proteome Software Inc., Portland, OR)
through searching with X! Tandem (version 2010.12.01.1, GPM Organization). Glu → pyro-Glu of the
N-terminus, ammonia-loss of the N-terminus, Gln →pyro-Glu of the N-terminus and oxidation of methionine
were specified in X! Tandem. Peptide identifications were accepted if they could be established at greater than
95% by the Scaffold Local FDR algorithm. Protein identifications were accepted if they could be established at
greater than 99.0% probability and contained at least 2 identified peptides. Protein probabilities were assigned by
the Protein Prophet algorithm53. Proteins that contained similar peptides and could not be differentiated based on
MS/MS alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence
were grouped into clusters. Fold changes in enrichment between probe-treated and control samples were calculated using total weighted spectra; in cases where no spectral counts were observed (zero), those were imputated
to a value of 1 in the Scaffold software for subsequent analysis.
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